中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (12): 906-908.doi: 10.12144/zgmfskin202312906

• 病例报告 • 上一篇    下一篇

高选择性JAK1抑制剂治疗难治性大疱性类天疱疮一例

孙琳,董正邦,王飞   

  1. 南京东南大学附属中大医院皮肤科，江苏南京，210009
  • 出版日期:2023-12-15 发布日期:2023-11-22

Highly selective JAK1 inhibitor for the treatment of refractory bullous pemphigoid: a case report

SUN Lin, DONG Zhengbang, WANG Fei   

  1. Zhongda Hospital Southeast University, Nanjing 210009, China
  • Online:2023-12-15 Published:2023-11-22

PDF (PC)

61

摘要： 本文报道一例难治性大疱性类天疱疮患者，起初给予糖皮质激素治疗，效果欠佳，改用利妥昔单抗治疗，皮疹反复伴剧烈瘙痒，后口服JAK1抑制剂阿布昔替尼治疗，瘙痒快速缓解，随访皮疹无复发。

关键词: 大疱性类天疱疮, 瘙痒, JAK抑制剂, 不良反应

Abstract: We report a patient with refractory bullous pemphigoid was treated with glucocorticoid at first, but the effect was poor. Rituximab was used for treatment, and the rash recurred with severe pruritus. After oral administration of the JAK1 inhibitor abrocitinib, the pruritus was rapidly relieved, and there was no recurrence of the rash during follow-up.

Key words: bullous pemphigoid, pruritus, JAK inhibitors, adverse effects